Aptevo Therapeutics Inc. announced that it has resumed IXINITY® manufacturing operations and anticipates that new supply of IXINITY will be available beginning in the second quarter of 2017. The IXINITY supply interruption relates to ongoing bulk drug substance (BDS) manufacturing challenges, which Aptevo believes have now been addressed.